Abstract: A pharmaceutical composition for the treatment of a liver disorder, comprising as an effective agent against liver dysfunction, a mixture in effective amounts of the components:(a) L-Asparaginic acid;(b) L-Cysteine;(c) L-Glutaminic acid;(d) sodium selenate; and(e) zinc acetate or zinc sulfate in the following proportions: 0.020 to 2.00:0.025 to 1.00: 0.025 to 5.00:28.10.sup.-6 to 500.10.sup.-6 :0.010 to 0.300 by weight.
Abstract: A method for the prevention and control of hypoxic damage resulting from stroke or other cerebral ischemic event which comprises administering pharmaceutical compositions containing 2-phenyl-1, 3-propanediol dicarbamate as an active ingredient.
Abstract: The biliproteins delta-bilirubin and delta-bilipeptide are useful as a cytoprotective antioxidants. Delta-bilipeptide as the term is used herein is a truncated form of delta-bilirubin in which an albumin analogue of 10-200 amino acid residues replaces the albumin portion of delta-bilirubin. Patient-administrable compositions for addition to a patient's blood to minimize oxyradical damage caused by ischemia-reperfusion injury that may result in various surgical procedures, and comprising delta-bilirubin or delta-bilipeptide, are described.
Abstract: A lipid composition having a high .gamma.-linolenic acid content is prepared by culturing mold fungi of the genus Cunninghamella in an aqueous nutrient culture medium having a relatively high concentration of a carbon source, and the lipid composition is recovered from the cultured mold fungi.
Abstract: A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more known uricosurics are also set forth.
Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
Type:
Grant
Filed:
March 5, 1990
Date of Patent:
May 14, 1991
Assignee:
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Inventors:
John T. Suh, Robert G. Pendleton, Charles E. Pendley, II, Kin T. Yu, Paul R. Menard, Alain B. Schreiber
Abstract: A method for treating shock in a patient, which comprises administering to the patient a therapeutically effective amount of a diazepinone of the general formula: ##STR1## wherein A represents a 5,11-dihydro-6H-pyrido[2,3-b] [1,4] benzodiazepin-6-one group bound in the 11-position; a 5,10-dihydro-11H-dibenzo [b,e] [1,4] diazepin-11-one group bound in the 5-position; a 5,11-dihydro-10H-pyrido [3-2b] [1-4] benzodiazepin-10-one group bound in the 5-position; a 4,9-dihydro-10H-thieno [3,4-b] [1,5] benzodiazpin-10-one group bound in the 4-position, unsubstituted or substituted at the 1- or 3-position or both in the 1- and 3-position by an alkyl group having from 1 to 4 carbon atoms, or in the 3-positionby chlorine, fluorine or bromine; a 6-11-dihydro-5H-pyrido [2,3-b] [1,5] benzodiazepin-5-one group bound in the 11-position; or a 1-methyl-1,4,9,10-tetrahydropyrrolo-[3,2-b] [1,5] benzodiazepin-10-one group bound in the 4-position, unsubstituted or substituted at the 3-position by methyl or methyl or chlorine;R.sub.
Type:
Grant
Filed:
May 17, 1989
Date of Patent:
March 19, 1991
Assignee:
Dr. Karl Thomae GmbH
Inventors:
Wolfgang Eberlein, Volker Trach, Wolfhard Engel, Gerhard Mihm, Norbert Mayer, Henri Doods, Richard Reichl